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ABSTRACT 
Objective: Development of a simple, rapid and accurate vierordt’s method or simultaneous equation (SE) method for the simultaneous estimation 
of Buprenorphine HCl (BU) and Naloxone HCl (NA) in bulk and pharmaceutical dosage form. The proposed method was validated according to the 
guidelines of the International Conference on Harmonization and the Association of Official Analytical Chemists International.  
Methods: The method was based on the measurement of absorbance at two wavelengths 289.0 nm and 283.8 nm, λmax
Results: Calibration curves were linear in the concentration range of 40-200 µg ml
 of BU and NA in methanol 
respectively.  
-1 for BU and 40-260 µg ml-1 for NA. The mean recovery, limit of 
quantification (LOQ) and limit of detection (LOD) for BU were 98.91 %, 0.481 µg ml-1 and 0.158 µg ml-1 and for NA were 98.85 %, 1.283 µg ml-1 and 
0.423 µg ml-1
Conclusion: The proposed method can be successfully applied for simultaneous estimation of BU and NA in bulk and pharmaceutical dosage form. 
, respectively. The method was precise, with a relative standard deviation of less than 2.0 % for both drugs. For robustness, the factors 
analyzed did not significantly affect the quantification of BU and NA.  
Keywords: Vierordt’s method, Simultaneous equation method, Buprenorphine HCl, Naloxone HCl. 
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INTRODUCTION 
Buprenorphine hydrochloride (BU) is chemically known as (6R, 7R, 
14S)-17cyclopropylmethyl-7, 8-dihydro-7-[(l S)-1-hydroxy-1, 2, 
2trimethylpropyl]-6-0-methyl-6, 14-ethano-17-normorphine hydro-
chloride [1-4]. The molecular formula of BU is C 29H41NO4
Naloxone hydrochloride (NA) is chemically known as Morphinan-6-one, 
4, 5-epoxy-3, 14-dihydroxy-17-(2-propenyl), hydrochloride [7, 2-4]. The 
empirical formula of NA is C
, HCl and 
the molecular weight is 504.1 (fig.1). It is a potent semi-synthetic 
opiate analgesic with a potency of 20-40 times higher than that of 
morphine [5]. As an analgesic, it has been used successfully by 
intramuscular, intravenous or sublingual routes for the treatment of 
moderate to severe pain as well as chronic pain [6]. 
19H21NO4
BU, opioid narcotic analgesic available in various dosage forms in 
the US market. BU has abused potential and creates dependence. 
Thus it is given in combination with its antagonist NA. A few 
examples of combinatorial dosage forms of BU and NA currently 
available in the market in different dosage forms by their trade 
names are SUBOXONE
, HCl and the molecular weight is 
363.84 (fig. 1). It is a potent opioid antagonist and is a competitive 
antagonist at mu, delta and kappa opioid receptors [6]. 
® and QUDICT® sublingual tablet; 
SUBOXONE® sublingual film and BUNAVAIL®
A detailed survey of literature revealed that very few analytical 
methods have been reported for the estimation of BU [1, 8, 9] and 
NA [7, 10, 11] individually and in combined dosage form [12, 13] 
using High Performance Liquid Chromatography (HPLC), Reversed 
Phase High Performance Liquid Chromatographic (RP-HPLC) and 
non-aqueous titration method. A single spectrophotometric method 
has been reported for estimation of BU in raw material but its 
estimation depended upon an ion pair formation and extraction 
process which is time-consuming and interference error may occur 
[9]. An analytical method has also been described for the estimation 
of BU and NA in biological fluids [14]. 
 buccal film. 
No spectrophotometric analytical method has yet been reported in 
the official compendia for the simultaneous determination of BU and 
NA in pharmaceutical dosage forms. The present study attempted to 
develop a rapid, economical, precise and accurate method for 
simultaneous determination of BU and NA.  
The simultaneous estimation method or vierordt’s method permits 
simultaneous analysis of both compounds without previous 
separation and extraction procedures. This alternative is simpler 
and less expensive than HPLC methods [8, 10-12]. 
A detailed survey of literature also revealed that scientist has 
previously used this simultaneous estimation method for estimation 
of metoprolol succinate and olmesartan medoxomil in tablet dosage 
form [15]; for estimation of dutasteride and tamsulosin 
hydrochloride in tablet dosage form by vierordt’s method [16]; for 
estimation of paracetamol and flupirtine maleate in pure and 
pharmaceutical dosage form [17].  
The objective of the present study was to develop a simple, precise, 
accurate and rapid SE method for the estimation of BU and NA in 
pharmaceutical dosage form. 
MATERIALS AND METHODS 
Apparatus 
Shimadzu 1800 UV–Vis double beam spectrophotometer with UV 
probe software and 1 cm matched quartz cells was used. 
Materials 
Buprenorphine HCl USP and Naloxone HCl USP were procured from 
Sun Pharmaceuticals Industries Ltd. Analytical grade methanol 
(Merk Ltd.) was used throughout these experiments.  
Standard solutions 
Stock solutions of BU and NA were prepared by dissolving 20.0 mg 
of BU and NA separately in methanol in 50 ml volumetric flasks, and 
sonicated for 5 min. Final volumes of both the solutions were 
adjusted with methanol to get stock solutions with the concentration 
of 400.0 µg ml-1 of BU and NA. 
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Working standard solutions  
Working standard solutions of BU was prepared by pipetting 5.0 ml 
of BU standard solution of 400.0 µg ml-1 in a 10 ml volumetric flask & 
working standard solutions of NA was prepared by pipetting 5.0 ml 
of NA standard solution of 400.0 µg ml-1 in a 20 ml volumetric flask. 
Final volumes of both the solutions were adjusted with methanol to 
get working standard solutions with the concentration of 200.0 µg 
ml-1 of BU and 100.0 µg ml-1 of NA. The concentration range of 40, 
60, 80, 100, 120, 140, 160, 180, 200 µg ml-1 was prepared for BU and 
40, 60, 80, 100, 120, 140, 160, 180, 200, 220, 240, 260 µg ml-1 
The sample solution was prepared using developed BU and NA 
sublingual tablet. A number of 20 accurately weighed tablets were 
ground into a fine powder using a glass mortar and pestle. A portion 
equivalent to 4.0 mg of BU and 4.0 mg of NA was accurately weighed 
and transferred to a 20 ml volumetric flask and volume was made up 
with methanol. The resulting solution was then sonicated for 5 min 
& then the final concentration of 200.0 µg ml
for NA 




 of BU and NA was 
obtained.  
Selection of wavelengths 
The working standard solutions of BU and NA were then scanned 
from 250 to 400 nm with the UV spectrophotometer using methanol 
as a blank. The UV spectrum of BU [18, 19] and NA [20] was shown 
in the fig.1; thus the λmax of BU and NA was found to be 289.0 nm 
and 283.8 nm in methanol, respectively & the overlain spectra of BU 
& NA is shown in fig. 1. 
 
 
Fig. 1: Overlain spectra of buprenorphine HCl and naloxone HCl 
 
 
Fig. 2: UV spectra of the mixture containing buprenorphine HCl and naloxone HCl 
 
 
Fig. 3: Calibration graph for buprenorphine HCl 
 
Fig. 4: Calibration graph for naloxone HCl 
Buprenorphine 
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Validation of the concentration range  
The absorbance were measured for BU and NA in the concentration 
range of 40, 60, 80, 100, 120, 140, 160, 180, 200 µg ml-1 and 40, 60, 
80, 100, 120, 140, 160, 180, 200, 220, 240, 260 µg ml-1
Calibration graphs were plotted for BU at 289.0 nm and NA at 
283.8 nm at a concentration range of 40-200 µg ml
 at 289.0 nm 
and 283.8 nm for both the drugs respectively.  
-1 for BU and 
40-260 µg ml-1
Determination of absorptivity value 
 for NA, respectively as shown in fig. 3 & 4. 
The absorptivity of each solution was calculated by using the 
following formula:  
Absorptivity = Absorbance/concentration (g/100 ml) 
Theory 
Simultaneous equation method OR Vierordt’s method 
If the sample contains two absorbing drug (X, Y) each of which 
absorbs at the λmax
For solving this equation the following information is required:  
 of the other, then both the drugs can be 
quantified by using simultaneous equation method [21-23]. 
(a) The absorptivities of pure drug X at λ1 and λ2, ax1 and ax2
(b) The absorptivities of pure drug Y at λ
 
respectively. 
1 and λ2, ay1 and ay2
(c) The absorbance of diluted sample at λ
 
respectively. 




x and cy be the concentration of X and Y respectively in the 
diluted sample. Two equation are constructed based upon the fact 
that at λ1 and λ2 
At λ
the absorbance of the mixture is the sum of the 
individual absorbance of X and Y. 
1 A1= ax1b cx+ay1b cy.
At λ
......... (Eq. 1) 
2 A2= ax2 b cx+ay2 b cy................  
For measurement in 1 cm cells, b=1. 
(Eq. 2) 
The concentrations of drugs in sample solutions were determined by 
using the following formula:  





 (Eq. 4) 
1 and λ2 
C
are the maximum wavelengths of BU and NA, 
x and Cy
ax
 are the concentration of BU and NA,  
1 and ax2
ay
 are absorptivities of BU at 289.0 nm and 283.8 nm,  
1 and ay2
Method validation 
 are absorptivities of NA at 289.0 nm and 283.8 nm, 
respectively. 
Validation of this new simultaneous spectrophotometric method 
was carried out as recommended by the International Conference on 
Harmonization ICH (ICH Q2A & Q2B) guidelines [24, 25] and the 
Association of Official Analytical Chemists International (AOAC, 
2005) [26] for the parameters of specificity, linearity, accuracy, 
precision, limit of detection (LOD), limit of quantification (LOQ) and 
robustness. 
Specificity 
The specificity of the method was evaluated through analysis of a 
placebo solution. The mixture of inert components was prepared 
in the usual concentrations employed in developed BU and NA 
sublingual tablet.  
These solutions were analyzed by the proposed method in order 
to determine if any of the components of the formulation might 
affect the determinations of BU and NA. 
Linearity 
Linearity was determined from the calibration graphs plotted for BU 
and NA at 289.0 nm and 283.8 nm respectively. All 
spectrophotometric determinations were performed in triplicate 
and at room temperature (25±2  ̊C). The linear regression was 
calculated by the method of least squares, and the calibration curves 
were evaluated by analysis of variance (ANOVA). 
Accuracy 
The accuracy was calculated based on the percentage of recovery of the 
known amounts of BU and NA added to the samples [24-26]. Aliquots of 
the BU and NA standard solutions in concentrations of 200, 250 and 300 
µg ml-1
Precision 
 were transferred to 10 ml volumetric flasks containing 5 ml of the 
sample solution. The volumes were made up with methanol and the 
drugs were determined in triplicate, using the proposed method. 
The intra-day precision (repeatability) was evaluated by analyzing 
sample solutions at single concentrations of BU and NA. The 
analyses were performed in triplicate on the same day. To estimate 
the inter-day precision, the sample solutions were freshly prepared 
at the same concentration level for each drug, and the responses 
were determined in triplicate. This procedure was performed on 
three consecutive days. The intra-and inter-day precisions are 
expressed in terms of relative standard deviation (% RSD). 
Limits of detection and quantitation (LOD and LOQ) 
LOD and LOQ were calculated based on the standard deviation of the 
response and the slope of the calibration curve. The standard 
deviation of y-intercepts of regression lines was used as the 
standard deviation of responses [24-26]. These values were 
obtained using the following equations:  
LOD = 3.3 σ/S (Eq. 5) 
LOQ = 10.0 σ/S (Eq. 6) 
Where, σ = the standard deviation of the response  
S = the slope of the calibration curve 
Robustness  
Robustness study was carried out by changing the wavelength in ±1 
nm of 289.0 nm and 283.8 nm.  
RESULTS AND DISCUSSION 
Method development 
BU and NA are highly soluble in methanol i.e. 42.0 mg/ml and 50.0 
mg/ml respectively. Hence it is used as a solvent for standard and 
sample preparation [27, 28]. The use of vierordt’s or SE method 
allowed these drugs to be determined simultaneously. The 
absorbance values were taken at 289.0 nm for BU and at 283.8 nm 
for NA respectively and then the calibration curves were plotted at 
their respective wavelength for both the drugs as presented in the 
fig. 3 & 4 and their absorptivity values were calculated for each 
concentration as shown in table 1 & 2. 
Method validation 
Specificity 
The specificity test demonstrated that the excipients did not affect 
the drug determination as depicted in the fig. 5 & 6, respectively. 
Thus, no interference was observed at 289.0 nm and 283.9 nm 
indicated that the method is specific. 
Linearity 
The statistical results of the linear regression for BU and NA are 
shown in table 3. The coefficient of determination indicated good 
linearity: 0.997 and 0.998 for BU and NA, respectively. The linearity 
ranges were 40-200 µg ml-1 for BU and 40-260 µg ml-1 for NA. The 
absorbance values for these concentration ranges remained between 
0.1 and 0.9, conforming to the recommendations of Vogel [23]. The 
Mundhey et al. 
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RP–HPLC method for the estimation of BU & NA in pharmaceutical 
dosage forms shows a smaller range of concentrations [22]. 
Accuracy 
The recovery percentages were 98.91 % and 98.85 % along with % 
RSD 0.639 and 0.896 for BU and NA, respectively (table 4). These 
results indicate the accuracy of the method. 
Precision 
The precision parameters (% RSD) expressed as repeatability 
(intraday) and as intermediate precision (inter-day) are presented in 
table 5. For BU and NA, all % RSD were valued were lower than 1% for 
repeatability in analyses performed during 3 consecutive days, and 
also for intermediate precision. Thus, the proposed method has good 
precision in the simultaneous determination of BU and NA. 
 





Absorptivity Absorbance Absorptivity 
λ1 λ(289 nm) 1 λ(289 nm) 2 λ(283.8 nm) 2 (283.8 nm) 
40 0.155 38.75 0.143 35.75 
60 0.239 39.83 0.219 36.50 
80 0.328 41.00 0.302 37.75 
100 0.418 41.80 0.384 38.37 
120 0.471 39.25 0.432 36.00 
140 0.555 39.64 0.508 36.33 
160 0.643 40.21 0.590 36.85 
180 0.732 40.65 0.669 37.18 
200 0.834 41.72 0.769 38.45 
 Mean Absorptivity at 289 nm (λ1
(M±SD) 
) 40.316±1.06 Mean Absorptivity at 283.8 nm (λ2
(M±SD) 
) 37.021±0.99 
 λ1-maximum wavelength of BU, λ2-
 
maximum wavelength of NA, M-mean and SD-Standard deviation 





Absorptivity Absorbance Absorptivity 
λ2 λ(283.8 nm) 2 λ(283.8 nm) 1 λ(289 nm) 1(289 nm) 
40 0.161 40.25 0.142 35.50 
60 0.244 40.67 0.217 36.17 
80 0.330 41.21 0.294 36.79 
100 0.412 41.20 0.369 36.90 
120 0.452 37.67 0.404 33.69 
140 0.530 37.81 0.473 33.79 
160 0.605 37.83 0.542 33.85 
180 0.678 37.65 0.607 33.70 
200 0.758 37.87 0.678 33.90 
220 0.837 38.03 0.749 34.05 
240 0.916 38.14 0.820 34.18 
260 0.990 38.05 0.887 34.12 
 Mean Absorptivity at 283.8 nm (λ2
(M±SD) 
) 38.864±1.47 Mean Absorptivity at 289 nm (λ1
(M±SD) 
) 34.719±1.25 
 λ1-maximum wavelength of BU, λ2-
 
maximum wavelength of NA, M-mean and SD-Standard deviation 
 
Fig. 5: Graphical evidence that no interference exists between the Buprenorphine HCl and excipients of developed sublingual tablet 
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Table 3: Statistical and validation parameter 
Statistical parameters BU NA 
λ 289.0 nm max 283.8 nm 
Linearity range (µg ml-1 40-200 ) 40-260 









Coefficient of determination (R2 0.997 ) 0.998 
Significant slope (p-valuea <0.0001 ) <0.0001 
LOD (µg ml-1 0.158 ) 0.423 
LOQ (µg ml-1 0.481 ) 1.283 
 λmax–maximum wavelength, a
 
 Theoretical value of p is based on one–way ANOVA test, at α = 0.05 level of significance 
 
Fig. 6: Graphical evidence that no interference exists between the Naloxone HCl and excipients of developed sublingual tablet 
 
Table 4: Recovery data for standard solutions added to the samples analysed by simultaneous equation method 












BU 120 119.69 1.092 99.74 98.91 0.639 
125 122.81 0.648 98.25 
130 128.35 0.524 98.73 
NA 120 119.27 1.151 99.39 98.85 0.896 
125 122.56 0.619 98.04 
130 129.37 0.666 98.52 
RSD–relative standard deviation a
 
mean of 3 determinations 




























0 hr 0.200 100.291  
99.42 
 




4 hr 0.197 98.708 0.266 102.393 
8 hr 0.199 99.916 0.265 102.264 
Inter day 
precision 
Ist 0.199  day 99.421  
100.01 
 




IInd 0.200  day 100.083 0.266 102.649 
IIIrd 0.195  day 97.916 0.267 103.034 
SD–standard deviation and RSD–relative standard deviation 
 
Limits of detection and quantitation (LOD and LOQ) 
The LODs were 0.158 µg ml-1 and 0.423 µg ml-1 for BU and NA, and 
the LOQs were 0.481 µg ml-1 and 1.283 µg ml-1
The responses of BU and NA did not change significantly when the 
analytical conditions were modified (table 6). These observations 
confirm the robustness of the method for determination of BU and 
NA in pure and pharmaceutical dosage form. 
 for BU and NA, 
respectively. These values show that the proposed method has good 
sensitivity and results are presented in table 3. 
Robustness 
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288 0.196 98.33 0.086 282.8 0.264 101.62 0.072 
290 0.196 98.08 0.087 284.8 0.264 101.88 0.072 
RSD–relative standard deviation 
 
The objective of this study was to develop and validate a simple & 
specific UV spectrophotometric method for simultaneous 
determination of BU and NA. As the λmax of BU and NA are closer 
together and not even exhibiting a difference of ±10 nm, henceforth 
no isoabsorption point (λ iso) was exhibited as seen in fig. 2, hence 
estimation of both BU & NA was not possible using absorptive ratio 
method. Henceforth simultaneous estimation or vierordt’s method 
was selected for determination of BU and NA in combined dosage 
forms. This method exhibited precise, accurate and cost effective 
assay for these drugs in the mixture. Based on previous studies, 
Mostafavi A et al., (2009) developed and validated a simple isocratic 
RP-HPLC method for the simultaneous determination of BU, NA 
dehydrate and its major impurity noroxymorphone in 
pharmaceutical tablets [12]. The developed method was linear in the 
range of 0.22–220 µg mL-1 and 0.1–100 µg mL-1 
The developed method was linear in a range of 2.0-12.0 µg mL
for BU and NA, 
respectively & the recovery studies for all these three compounds 
were above 96%. Damodar K et al., (2011) developed and validated 
a simple & accurate RP-HPLC method for the estimation of BU and 
NA in pharmaceutical dosage forms.  
-1 for 
both the drugs & the RSD values for accuracy & precision studies 
were less than 2 % [13]. Sun W et al., (2014) developed a method for 
the simultaneous determination of NA, BU and norbuprenorphine in 
human plasma using hollow fiber liquid phase microextraction 
combined with ultra HPLC & tandem mass spectrometry. The 
method was linear in the range of 0.1–25 ng mL-1
CONCLUSION 
 & the recoveries 
were in the range of 92.1–106.0% with RSD values were less than 
15% [14]. Literature survey revealed a single spectrophotometric 
method for the determination of BU in raw material or in 
pharmaceutical formulations [9]. However, this method involved an 
ion pair complex formation between BU & bromocresol green which 
resulted into a tedious & more time-consuming process. Though 
above-mentioned processes for the simultaneous analysis of BU and 
NA are more sensitive than present method, however all the 
previous methodologies involved the use of highly sensitive 
apparatus like HPLC & hyphenated instruments such as UHPLC-
MS/MS along with costly organic solvents required for mobile phase 
development as compared to UV spectrophotometer as employed in 
this study. The present method using UV spectrophotometer is more 
cost efficient & less time consuming.  
A UV spectrophotometric method was developed and validated for 
the simultaneous determination of BU and NA in bulk and 
pharmaceutical dosage formulations. The method showed precision, 
accuracy, LOD, LOQ and robustness, as evaluated according to ICH 
guidelines. The proposed method proved to be simpler, less 
expensive, and faster, because no additional pre-treatment of the 
samples is required prior to the measuring step, thus accelerating 
the quality-control process. Thus the UV simultaneous equation 
method was suitable, useful, and an excellent alternative to HPLC to 
assess quality in routine analysis of BU and NA in drug products. 
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